Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2000-04-14
2002-04-02
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S163100, C424S164100, C424S159100, C424S196110
Reexamination Certificate
active
06365156
ABSTRACT:
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable.
BACKGROUND OF THE INVENTION
The use of soluble viral receptors to prevent viral infection is being actively pursued. Amongst these efforts, intranasal administration of soluble ICAM-1 is being tested to prevent rhinovirus (cold) infection (Boehringer Ingelheim and Bayer). Soluble viral receptors are designed to work by engaging all host binding sites of a virus, thereby leaving none for the virus to attach to its target cell. However, a single viral particle has numerous binding sites for the host cell on its surface, e.g. rhinovirus has 60. Soluble viral receptors must simultaneously coat all binding sites on the virus to render it non-infectious. This requires an extremely high ratio of soluble viral receptors to viral particles (e.g. >60:1 for rhinovirus). Furthermore, since binding is a reversible process, it is unlikely that all binding sites on a virus could be coated simultaneously. Theoretically, even one free binding site on a virus would still allow it to be infectious to the host.
Clinical trials with soluble viral receptors to prevent viral infection have been met with limited success. Soluble ICAM-1 receptors were found to be only minimally effective in preventing cold infections, and only if they were already present on the nasal mucosa at the time of encounter with rhinovirus. Since an infected host is unaware of any symptoms until 2 to 3 days after an infection occurs, the only way to ensure that soluble viral receptors are present on the nasal mucosa at the time of infection is to apply them regularly throughout a period of presumed risk.
In particular, there is a problem of the short half-life of the soluble viral receptors on the mucosal surface. Since soluble viral receptors are freely mobile, they can be easily washed out by the normal mucociliary clearance mechanisms. This translates into a need for frequent reapplications. Subjects in the ICAM study had to apply the soluble viral receptors six times per day. This will likely translate into high cost and poor compliance, making soluble ICAM-1 receptor therapy an impractical approach for preventing cold infections.
The purpose of this invention is to improve the half-life of soluble viral-specific ligands on mucosal membranes, thereby reducing the cost and application frequency associated with the use of soluble viral-specific ligands to prevent viral infection.
REFERENCES:
patent: 5348867 (1994-09-01), Georgiou et al.
patent: 5531988 (1996-07-01), Paul
patent: 5733540 (1998-03-01), Lee
patent: 6074636 (2000-06-01), Nichols
patent: WO 93/18163 (1993-09-01), None
Eko et al. Mar. 1999. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine. vol. 17, pp. 1643-1649.*
Baba et al. 1996. Target cell specificity of a bacteriocin molecule: a C-terminal signal directs lysostaphin to the cell wall of Staphylococcus aureus. The EMBO Journal. vol. 15. No. 18, pp. 4789-4797.*
Braun et al. 1998. The InlB protein of Listeria monocytogenes is sufficient to promote entry into mammalian cells. Molecular Microbiology. vol. 27. No. 5, pp. 1077-1087.*
Marshall, E., “Gene Therapy's Growing Pains, ”Science, 269:1050-1055 (Aug. 25, 1995).
Lidbeck, A., et al., “Lactobacilli in Relation to Human Ecology and Antimicrobial Therapy,” 1991 Bioscience Ediprint, Inc., Int. J. Tiss. Reac. XIII(2):115-122 (1991).
Bouhnik, Y., et al., “Fecal Recovery in Humans of Viable Bifidobacterium sp Ingested in Fermented Milk,” 1992 by the American Gastroenterological Association,Gastroenterology, 102:875-878 (1992).
Pochart, P., et al., “Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion1-4,” 1992 American Society for Clinical Nutrition,Am J Clin Nutr55:78-80 (1992).
Laulund, S., “Commercial Aspects of Formulation, Production and Marketing of Probiotic Products,” Human Health: The Contribution of Microorganisms Formulation, Production and Marketing of Probiotic Products, Chapter 10, 159-173 (1994).
Foley Shanon A.
Housel James
Osel, Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Method for improving the half-life of soluble viral-specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for improving the half-life of soluble viral-specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for improving the half-life of soluble viral-specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2905554